ENDOCRINE SYSTEM

1. ANTIDIABETICS

1. INSULIN HUMAN, rDNA

JUSLINE

Presentation

Jusline R:

10mL 100 units per mL in a vial Solution for Injection in a vial Insulin human, rDNA

Jusline N:

10mL 100 units per mL in a vial Suspension for Injection in a vial Insulin human, rDNA isophane (NPH)

Jusline 30/70:

10mL 100 units per mL in a vial Solution for Injection in a vial Insulin human, rDNA (30% as soluble insulin and 70% as isophane insulin)

Indication

Diabetes mellitus

Dosage

Dosage is individual and determined in accordance with the needs of the patients. The individual insulin requirement is usually between 0.3 and 1.0 IU/kg/day. The daily insulin requirement may be higher in patients with insulin resistance (e.g. during puberty or due to obesity) and lower in patients with residual, endogenous insulin production.

In patients with diabetes mellitus optimised glycemic control delays the onset of late diabetic complications. Close blood glucose monitoring is recommended.

Jusline® (**R & 30/70**): An injection should be followed within 30 minutes by a meal or snack containing carbohydrates.

Jusline® (**N**): The physician determines whether one or several daily injections are necessary. **Jusline**® (**N**) may be used alone or mixed with fast-acting insulin. In intensive insulin therapy the suspension may be used as basal insulin (evening and/or morning injection) with fast-acting insulin given at meals.

